I'm LongbridgeAI, I can summarize articles.Novavax (NVAX) gained 5.14% this week, closing at $10.63. Trading was choppy but tilted upward: the stock opened around $10.38 on Monday, spiked to a weekly high of $11.09 on Tuesday (22 Sep), then settled into a range of $10.33 to $10.79 through Friday. There were no company-specific catalysts during the week, with activity largely driven by healthcare and innovation drug themes across the sector.
The Week
Novavax (NVAX) gained 5.14% this week, closing at $10.63. Trading was choppy but tilted upward: the stock opened around $10.38 on Monday, spiked to a weekly high of $11.09 on Tuesday (22 Sep), then settled into a range of $10.33 to $10.79 through Friday. There were no company-specific catalysts during the week, with activity largely driven by healthcare and innovation drug themes across the sector.
Analyst Ratings
Coverage consists of 9 institutions: 5 rate it buy, 1 hold, 2 underweight and 1 sell. The consensus recommendation is buy, with a consensus target of about $14.00, which sits 31.72% above the latest price of $10.63. Targets range from $7.00 to $25.00, reflecting wide dispersion. Within the biotechnology industry, Novavax ranks 160th out of 506 companies.
The Week Ahead
The macro calendar is busy next week. On Monday, 28 Sep, the US Dallas Fed manufacturing business activity index is due, with a prior reading of 11.6. Tuesday, 29 Sep, brings the FHFA house price index, Case Shiller 20-city home price index, JOLTS job openings (prior 7.271m) and consumer confidence (prior 89.4). No company earnings are scheduled; the focus remains on sector policy and vaccine-related developments.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.